US Patent 4,344,949: Claim Scope, Quinapril Protection, Expiration, and Patent Landscape

US Patent 4,344,949 is the foundational U.S. patent for quinapril and related substituted acyl tetrahydroisoquinoline compounds. Its claims cover a broad chemical genus, narrower structural subclasses, defined stereoisomers and salts, pharmaceutical compositions, and hypertension treatment methods. The patent issued on August 17, 1982, and its original 17-year term expired on August 17, 1999. No enforceable patent rights remain under this patent.

What drug does US Patent 4,344,949 protect?

The patent protects quinapril and related angiotensin-converting enzyme, or ACE, inhibitors.

The principal commercial compound is quinapril, marketed in the United States as Accupril by Warner-Lambert and later Pfizer. The active pharmaceutical ingredient is generally administered as quinapril hydrochloride. Quinapril is an ethyl ester prodrug that is hydrolyzed in vivo to quinaprilat, the pharmacologically active ACE inhibitor.

The compounds disclosed by the patent have three defining structural elements:

A 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid core.
An acyl-linked alanine-type side chain.
A substituted amino acid residue containing an ethoxycarbonyl group and a 3-phenylpropyl substituent.

The commercial quinapril structure falls within the stereochemically defined compounds in claims 5 through 13.

Patent identification

Item	Data
U.S. patent	4,344,949
Title	Substituted acyl compounds of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
Issue date	August 17, 1982
Technology	ACE inhibitors
Principal commercial compound	Quinapril
Commercial salt	Quinapril hydrochloride
Principal brand	Accupril
Original U.S. term	17 years from issue
Baseline expiration	August 17, 1999
Current status	Expired

The patent should be distinguished from later patents covering quinapril formulations, combination products, manufacturing processes, or regulatory exclusivity. Those rights, where applicable, did not extend the term of US 4,344,949 itself.

What does claim 1 of US 4,344,949 cover?

Claim 1 is a broad Markush genus claim covering substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and their pharmaceutically acceptable salts.

The claim includes variation at several positions:

Variable	Permitted substituents
R	Hydrogen, lower alkyl, or phenylalkyl
R1	Hydrogen, lower alkyl, or benzyl
R2	Hydrogen or lower alkyl
Ar	Phenyl or substituted phenyl
Ar substituents	Fluorine, chlorine, bromine, lower alkyl, lower alkoxy, hydroxy, or amino
X and Y	Hydrogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, or hydroxy
X and Y together	Methylenedioxy
m	0 to 3
Salts	Pharmaceutically acceptable salts

The claim uses functional and structural language rather than naming quinapril. A compound can therefore infringe claim 1 based on its chemical structure even if it is not called quinapril commercially.

The breadth comes from the combination of multiple independently variable substituents. The claim is not limited to:

Quinapril;
Quinapril hydrochloride;
The 6,7-dimethoxy analogue;
The unsubstituted ring analogue;
One particular dosage form; or
One particular method of manufacture.

The genus includes both esterified and acid forms, multiple N-substituents, different aromatic substituents, and several oxidation states for sulfur-containing substituents.

How do claims 2 through 4 narrow the chemical genus?

Claims 2 through 4 reduce the scope of claim 1 by limiting the substituent sets and then dividing the compounds into ring-substituted and unsubstituted subclasses.

Claim 2

Claim 2 limits the variables as follows:

R is hydrogen, tert-butyl, or benzyl;
R1 is hydrogen or lower alkyl;
R2 is hydrogen, methyl, or ethyl;
X and Y are hydrogen, lower alkyl, hydroxy, or lower alkoxy.

This removes several sulfur-containing substituents and excludes halogenated aromatic substituents permitted by claim 1.

Claim 3

Claim 3 depends on claim 2 and covers one specific structural arrangement in which the tetrahydroisoquinoline ring has the substitution pattern represented by formula STR7. The named compounds in claims 5, 8, 9, and 12 identify this class as the 6,7-dimethoxy series.

This class includes quinapril-related compounds with a 6,7-dimethoxy tetrahydroisoquinoline ring.

Claim 4

Claim 4 depends on claim 2 and covers the alternative arrangement represented by formula STR8. The compounds in claims 6, 7, 10, 11, and 13 identify this class as the unsubstituted tetrahydroisoquinoline series.

The distinction between claims 3 and 4 is commercially important because the 6,7-dimethoxy and unsubstituted analogues have different chemical identities and different claim dependencies.

What compounds are specifically claimed in claims 5 through 13?

Claims 5 through 13 are narrow compound claims directed to particular stereoisomers, ester forms, acids, salts, and hydrates.

Claim	Principal subject matter
5	6,7-Dimethoxy compound; benzyl ester; maleate; S,S,S stereochemistry
6	Unsubstituted compound; benzyl ester; maleate; S,S,S stereochemistry
7	Unsubstituted compound; tert-butyl ester; S,S,S stereochemistry
8	6,7-Dimethoxy compound; ethyl ester; hydrochloride hydrate; S,S,S stereochemistry
9	6,7-Dimethoxy compound; free carboxylic acid; hydrochloride hydrate; S,S,S stereochemistry
10	Unsubstituted compound; ethyl ester; hydrochloride hydrate; S,S,S stereochemistry
11	Unsubstituted compound; free carboxylic acid; hydrochloride hemihydrate; S,S,S stereochemistry
12	6,7-Dimethoxy compound; ethyl ester; hydrochloride; S,S,S stereochemistry
13	Unsubstituted compound; ethyl ester; hydrochloride; S,S,S stereochemistry

Quinapril hydrochloride corresponds most closely to the ethyl ester hydrochloride compounds recited in claims 10, 12, and 13, depending on the ring substitution represented by the structural formula. The patent’s claim architecture separates:

The ethyl ester prodrug;
The active carboxylic acid;
Hydrochloride salts;
Hydrated and hemihydrated solid forms;
Maleate salts;
Benzyl and tert-butyl ester intermediates or analogues; and
Defined stereochemical configurations.

The repeated S,S,S designation is central. The claims are not generic claims to all stereoisomers. They identify a specific stereochemical arrangement at the relevant chiral centers.

What do claims 14 and 15 protect?

Claim 14: pharmaceutical composition

Claim 14 covers a pharmaceutical composition containing 10 to 500 mg of:

A compound falling within claim 1;
A mixture of such compounds; or
A pharmaceutically acceptable salt;

together with a pharmaceutically acceptable carrier.

The composition claim is broad in dosage-form terms. It does not require a tablet, capsule, solution, suspension, or specific excipient. It also does not require a particular release profile or bioavailability specification.

The 10-to-500 mg range creates a quantitative limitation. A formulation containing less than 10 mg or more than 500 mg per unit or administration could raise a claim-construction issue, depending on how the dosage limitation is interpreted. The claim does not expressly limit the composition to once-daily administration.

Claim 15: hypertension treatment method

Claim 15 covers treating hypertension by administering an effective amount of a claim 1 compound or pharmaceutically acceptable salt.

The method claim requires:

A patient or subject with hypertension;
Administration of a covered compound or salt; and
An effective amount.

It does not require a particular blood-pressure reduction, treatment duration, dosing schedule, route of administration, or combination therapy. The broad treatment language would have been significant during the patent term, particularly against products labeled for hypertension.

Because the patent has expired, claim 15 has no current blocking effect. Its historic relevance remains important for understanding the originator’s patent position and the scope of later regulatory listings.

How strong was the patent estate for quinapril?

The patent was strong in structure because it layered protection across several claim types:

Protection layer	Claims	Commercial relevance
Broad chemical genus	1	Captured numerous related ACE inhibitor structures
Narrow chemical subclasses	2-4	Focused protection on preferred ring and side-chain patterns
Specific compounds and salts	5-13	Protected quinapril-related stereoisomers and solid forms
Pharmaceutical compositions	14	Covered drug products containing the compounds
Therapeutic method	15	Covered hypertension treatment

The broadest practical protection came from claims 1 and 2. Claims 5 through 13 supplied fallback positions if the broader genus claims faced validity challenges. The composition and method claims added infringement theories against finished pharmaceutical products and labeled uses.

The estate’s principal weakness was that its effective life was limited by the pre-1995 U.S. patent term. A patent issued in 1982 generally ran for 17 years from issuance, regardless of the later commercial launch date. FDA approval in 1991 did not reset the patent term.

When did US Patent 4,344,949 lose exclusivity?

The patent’s original term expired on August 17, 1999, 17 years after issuance.

Event	Date
Patent issuance	August 17, 1982
Original 17-year term	August 17, 1982 to August 17, 1999
Patent expiration	August 17, 1999
Accupril FDA approval	1991
Post-expiration generic competition	Permitted, subject to applicable FDA approval requirements

The patent was therefore expired before the modern wave of quinapril generic approvals. Generic applicants did not need to wait for this patent to expire after filing a Paragraph IV certification. The patent expiration date was available as a statutory basis for an expiration certification.

What was the Orange Book status of quinapril?

Accupril was approved under NDA 019214. The FDA Orange Book identifies patents listed by the NDA holder and provides patent expiration and use-code information where applicable. US 4,344,949 was the principal foundational patent associated with quinapril’s original U.S. product protection.

The Orange Book’s legal function is limited. Listing does not establish validity or infringement. A listed patent can be challenged through:

A Paragraph IV certification;
A declaratory judgment action;
Patent litigation under the Hatch-Waxman framework; or
Post-grant and district-court validity proceedings, depending on timing.

Because US 4,344,949 expired in 1999, it is no longer an active Orange Book barrier to an ANDA applicant. Current commercial risk must instead be assessed against any later-listed patents, regulatory exclusivities, manufacturing patents, and product-specific formulation rights.

Which companies challenged quinapril exclusivity?

The principal competitive challenge to quinapril came through abbreviated new drug applications for quinapril hydrochloride tablets. Generic applicants included companies such as Teva, Mylan, Sandoz, and Lupin during the broader generic-entry period.

The exact applicant, approval, and litigation record must be matched to the relevant NDA, ANDA, dosage strength, and FDA approval date. US 4,344,949 itself was already expired by the time most meaningful generic competition developed. As a result, Paragraph IV litigation directed solely at this patent was less commercially significant than challenges to later patents or regulatory barriers.

No current Paragraph IV challenge can reinstate or extend an expired patent. A Paragraph IV certification is relevant only to an unexpired listed patent.

What patent litigation affected quinapril?

The key litigation risk during the patent’s life would have involved:

Whether a generic quinapril product fell within the claimed stereochemical structure;
Whether quinapril hydrochloride fell within the claimed salt and ester limitations;
Whether a generic label induced infringement of the hypertension method claim;
Whether the Markush genus was enabled across its full breadth;
Whether the specific stereochemical compounds were novel and nonobvious;
Whether solid-state forms and hydrates were separately patentable; and
Whether the composition dosage range was sufficiently definite.

For an expired patent, current litigation value is limited to historical disputes, damages periods, and claim-construction precedent. The patent cannot support an injunction against present-day generic manufacture or sale.

What manufacturing and formulation barriers remain after expiration?

Expiration of the core compound patent does not eliminate all technical barriers. A generic manufacturer still must address:

Stereochemical control over the S,S,S product;
Hydrolysis and degradation of the ethyl ester;
Salt formation and moisture control;
Particle-size and dissolution specifications;
Impurity profiling;
Bioequivalence;
Stability of quinapril hydrochloride;
Process reproducibility; and
Compliance with current good manufacturing practices.

The patent’s claims to hydrates and hemihydrates show that solid-state and salt-form control were recognized in the original disclosure. Those claims expired with the patent and do not independently block current production. Later patents could have created separate barriers, but they must be evaluated independently by jurisdiction, claim scope, and expiration date.

How does quinapril compare with competing ACE inhibitors?

Drug	Core patent strategy	Commercial position
Quinapril	Tetrahydroisoquinoline carboxylic acid derivatives; stereochemically defined ester and salt claims	Accupril
Enalapril	Proline-derived ACE inhibitor; ester prodrug and active diacid	Vasotec
Lisinopril	Non-ester ACE inhibitor related to enalaprilat	Prinivil, Zestril
Ramipril	Proline-derived ACE inhibitor with bicyclic structure	Altace
Perindopril	Ester prodrug with distinct bicyclic amino-acid architecture	Aceon
Benazepril	Ester prodrug with distinct ring system	Lotensin

Quinapril’s patent differentiation was the tetrahydroisoquinoline core combined with an amino-acid side chain and defined stereochemistry. Its claim scope did not generally reach chemically distinct ACE inhibitor classes such as lisinopril or ramipril.

What was the revenue exposure associated with US Patent 4,344,949?

Accupril generated significant branded revenue before generic entry, but the patent’s commercial life was unusual because the patent expired in 1999 while FDA approval occurred in 1991. The nominal eight-year period between approval and patent expiration limited the available branded exclusivity compared with products patented under the post-1995 20-year-from-filing regime.

Revenue exposure was concentrated in:

Quinapril tablets;
Quinapril hydrochloride;
Accupril;
Fixed-dose quinapril/hydrochlorothiazide products such as Accuretic; and
International versions of quinapril products.

The compound patent did not automatically protect every combination product or formulation. Those products required separate analysis of listed patents, formulation claims, combination claims, and regulatory exclusivity.

What geographic coverage did the patent provide?

US 4,344,949 provided rights only in the United States. Corresponding foreign patent families may have covered quinapril or related compounds in Europe, Japan, Canada, and other markets, but each jurisdiction had separate:

Filing dates;
Priority claims;
Prosecution histories;
Claim amendments;
Patent-term rules;
Supplementary protection certificates or extensions; and
Expiration dates.

A U.S. expiration did not necessarily establish simultaneous global freedom to operate. The international landscape required family-level review.

Key Takeaways

US 4,344,949 is the foundational quinapril patent.
Claims 1 and 2 cover broad and intermediate chemical genera.
Claims 3 and 4 divide the principal dimethoxy and unsubstituted structural classes.
Claims 5 through 13 cover defined stereoisomers, esters, acids, salts, hydrates, and hemihydrates.
Claim 14 covers pharmaceutical compositions containing 10 to 500 mg of covered compounds or salts.
Claim 15 covers treatment of hypertension with the claimed compounds.
The patent issued August 17, 1982, and expired August 17, 1999.
The patent no longer creates a U.S. barrier to quinapril generic entry.
Current risk must be assessed against later formulation, combination, manufacturing, regulatory, and foreign patents.
Patent expiration does not eliminate technical manufacturing requirements, particularly stereochemical control, salt formation, stability, and bioequivalence.

FAQs

Is quinapril still protected by US Patent 4,344,949?

No. US 4,344,949 expired on August 17, 1999.

Does the patent cover quinaprilat?

The patent claims include the corresponding carboxylic acid forms and pharmaceutically acceptable salts. Quinaprilat-related structures are represented by the acid compounds in claims 9 and 11, subject to the structural formulas and stereochemical limitations.

Does US 4,344,949 cover quinapril hydrochloride tablets?

Claims 10, 12, and 13 directly address hydrochloride forms of the relevant ethyl ester compounds. Claim 14 also covers pharmaceutical compositions containing a covered compound or salt in the specified dosage range.

Can a generic company launch quinapril without a Paragraph IV challenge to this patent?

Yes. Because US 4,344,949 expired in 1999, an applicant could rely on patent expiration rather than challenge an unexpired patent under Paragraph IV. Any later-listed patent would require separate analysis.

Are quinapril combination products protected by this patent?

Not automatically. Combination products such as quinapril/hydrochlorothiazide may fall within a composition claim only if they satisfy the claim limitations. Separate combination-product patents and Orange Book listings must be reviewed independently.

References

U.S. Patent No. 4,344,949. (1982). Substituted acyl compounds of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Code, Title 35, § 154. (2024). Contents and term of patent; provisional rights.
U.S. Code, Title 35, § 156. (2024). Extension of patent term.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0049605	⤷ Start Trial	SPC/GB93/099	United Kingdom	⤷ Start Trial
European Patent Office	0096157	⤷ Start Trial	SPC/GB95/011	United Kingdom	⤷ Start Trial
Austria	25974	⤷ Start Trial
Austria	26120	⤷ Start Trial
Australia	5299186	⤷ Start Trial
Australia	551239	⤷ Start Trial
Australia	563683	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,344,949

Summary for Patent: 4,344,949